DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
Atrial Fibrillation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atrial Fibrillation (US)
Atrial fibrillation (AF) is a common arrhythmia characterized by irregular, often rapid heartbeats in the atria, increasing the risk of stroke and cardiovascular complications. Management typically…
Paroxysmal Nocturnal Hemoglobinuria – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Chronic Obstructive Pulmonary Disease – Geographic Focus: China – COPD – China In-Depth (China)
COPD is a progressive respiratory condition that primarily affects adults, particularly smokers and individuals exposed to environmental pollutants. The COPD therapeutics market in China includes a…
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – IgA Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
